FairJourney Bio Opens Cryo-Electron Microscopy Structural Biology Facility in San Diego

FairJourney Bio (FJBio), a global antibody discovery contract research organization (CRO), has opened an advanced cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, California, significantly expanding its presence in the U.S. market and incorporating atomic-resolution structural biology directly into its antibody discovery platform.

“With our new cryo-EM services, we will help our customers to significantly save time and costs, and accelerate their workflows,” explained Dr. Werner Lanthaler, CEO, FairJourney Bio.

The facility houses a 300 kV cryo-EM infrastructure, including two ThermoFisher Titan Krios 5 systems, enabling native-state structure determination of antibody-target complexes. The launch adds a powerful approach in structural biology for antibody discovery to FJBio’s integrated discovery workflow, providing detailed insights across the R&D value chain; from epitope mapping and hit generation through to structure-guided lead optimization and candidate selection.

The cryo-EM services, launched in January 20261, complement FJBio’s antibody discovery and biologic development portfolio with rapid and detailed structural insights that are easily scalable and delivered within 2-3 weeks. The services enable scientists to visualize protein structures at atomic resolution, including protein-protein and protein-ligand complexes, providing high-quality and interpretable results to inform confident decision-making across programs.

“Structural biology has historically been a late-stage tool, used to confirm decisions already made,” commented Dr. Christopher Arthur, CSO Structural Biology, FairJourney Bio. “We are redefining that paradigm. In San Diego, we are building a premier, full-service cryo-EM CRO that brings together decades of deep expertise in sample preparation, data collection, and computational analysis, embedding structural insight at the very start of discovery, where it shapes epitope selection and determines which leads are worth advancing.”

The facility complements FJBio’s existing U.S. presence in San Francisco and its operations across Europe.